Merck Life Science A/S: Financial statements 2012
CVR: 20830131
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
Merck Life Science A/S (CVR 20830131) has filed annual accounts for 2012. In 2012, the company reported revenue of DKK 25,846,000 and a net result of DKK 4,273,000. The profit margin was 16.5%. Equity in the 2012 report amounted to DKK 19,975,000. The solvency ratio was 49.8%.
- Revenue
- DKK 25,846,000
- Gross Profit
- DKK 17,131,000
- Profit/Loss
- DKK 4,273,000
- Equity
- DKK 19,975,000
- Total Assets
- DKK 40,130,000
Official annual report
Keep an eye on Merck Life Science A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
On October 11, 2012, the company changed its name from LABKEMI DENMARK A/S to SIGMA-ALDRICH DENMARK ApS.
About Merck Life Science A/S
Merck Life Science A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1998. The company is registered under the industry Engroshandel med andre maskiner og andet udstyr. The company was previously named SIGMA-ALDRICH DENMARK A/S and SIGMA-ALDRICH DENMARK ApS. The management consists of Janecke Stokkebokjær Lundring. The board consists of Anders Gerner Petersen (chair), Janecke Stokkebokjær Lundring and Tiina Marjatta Puhakka. The company is owned by Merck Life Science N.V. The company has 24 employees (2026). In 2025, the company reported revenue of DKK 1,748,796,583 and a net result of DKK 79,492,665 compared with DKK 66,730,278 the year before. Equity in the 2025 report amounted to DKK 226,078,413.